Development and validation of a highly sensitive and robust LC-ESI-MS/MS method for simultaneous quantitation of simvastatin acid, amlodipine and valsartan in human plasma: Application to a clinical pharmacokinetic study

Biomedical Chromatography

Volumn 23, Issue 6, 2009, Pages 615-622

  Ramani, Addepalli V ^a   Sengupta, Pinaki ^a   Mullangi, Ramesh ^a,b  

^a DR REDDY'S LABORATORIES LTD   (India)

^b Jubilant Innovation   (India)

Author keywords

Amlodipine; Human plasma; Humans; LC MS MS; Method validation; Pharmacokinetics; Simvastatin acid; Valsartan

Indexed keywords

ACETONITRILE; ELECTROSPRAY IONIZATION; PLASMA (HUMAN);

AMLODIPINE; HUMAN; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS-MS; LC.MS/MS; METHOD VALIDATIONS; SIMVASTATIN; SIMVASTATIN ACID; VALSARTAN;

PHARMACOKINETICS;

ACETONITRILE; AMLODIPINE; AMMONIUM FORMATE; SIMVASTATIN; VALSARTAN; ACETONITRILE DERIVATIVE; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; SIMVASTATIN ACID; TETRAZOLE DERIVATIVE; VALINE;

AREA UNDER THE CURVE; ARTICLE; ASSAY; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS; BLOOD; CHEMISTRY; ECONOMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME; VALIDATION STUDY;

ACETONITRILES; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIMVASTATIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TETRAZOLES; TIME FACTORS; VALINE;

EID: 67651214387     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1161     Document Type: Article

References (18)

1. Abernethy DR. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80: 31-36.
2. Dams R, Huestis MA, Lambert WE and Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. Journal of American Society for Mass Spectrometry 2003; 14: 1290-1294.
3. Hubert Ph, Chiap P, Crommen J, Boulanger B, Chapuzet E, Mercier N, Bervoas-Martin S, Chevalier P, Grandjean D, Lagorce P, Lallier M, Laparra MC, Laurentie M and Nivet JC. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis Washington conférence to the laboratory. Analytica Chimica Acta 1999; 391: 135-148.
4. Jukema JW, Zeinderman AH, van Boven AJ, Reiber JH, Van der Laarse A, Lie KI and Bruschke AV. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arteriosclerosis, Thrombosis and Vascular Biology 1996; 16: 425-430.
5. Jukema JW, van Boven AJ, Zeinderman AH, Van der Laarse A and Bruschke AV. Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovascular Drugs and Therapy 1998; 12: 111-118.
6. Kannel WB. Risk stratification in hypertension: new insights form the Famingham Study. American Journal of Hypertension 2000; 1: 3S-10S.
7. Ledingham JM and Laverty R. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Clinical and Experimental Pharmacology & Physiology 2005; 32: 76-85.
8. Matsubara K, Yamamoto Y, Sonoyama K, Igawa G, Furuse M, Yatsuhashi T, Hamada T, Ogino K, Igawa O, Hisatome I and Shigemassa C. Current status of lipid management of hypertensive patients. Hypertension Research 2003; 26: 699-704.
9. Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H and Ohashi K, Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertension Research 2005; 28: 223-227.
10. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H and Pospiech R. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clinical Therapeutics 2007; 29: 563-580.
11. Prueksaritanont T, Gorham LM, Ma B. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism and Disposition 1990; 18: 138-145.
12. Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M and Pitt B. Effects of valsartan alone versus valsartan/ simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. American Journal of Cardiology 2007; 100: 222-226.
13. Sander GE and Giles TD. Hypertension and lipids: lipid factors in the hypertension syndrome. Current Hypertension Reports 2002; 4: 458-463.
14. Shepherd J. Preventing coronary artery disease in the West of Scotland: implications for primary prevention. American Journal of Cardiology 1998; 82: 57T-59T.
15. US DHHS, FDA, CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CV), 2001. Available at: http://www.fda.gov/ cder/guidance/index.htm
16. Vickers S, Duncan CA, Chen IW, Rosegay A and Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metabolsim and Disposition 1990a; 18: 138-145.
17. Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G and Duggan E. Drug Metabolism and Disposition 1990b; 18: 476-483.
18. Williams D and Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics 2002; 41: 343-370.